Considering Personalized Neoantigen Vaccine Approaches for Multiple Myeloma
Neoantigens may have the ability to provoke the immune system into recognizing and killing cancer cells in patients with multiple myeloma.
Multiple Myeloma
Comparison of Treatment With Bortezomib and Lenalidomide for Relapsed Multiple Myeloma
Progression-free survival, overall survival, and percentage of patients who achieved very good partial response or better were similar between both treatment groups.
Phase 2 Trial of Ibrutinib, Bortezomib, Dexamethasone Combination for R/R Multiple Myeloma Was Closed Early
Despite an overall response rate of 57%, this clinical trial was suspended due to safety concerns then closed early due to insufficient activity of the study drug combination.
MRD Status Assessed by Flow Cytometry Predicts Treatment Efficacy in Newly Diagnosed Multiple Myeloma
Next-generation flow cytometry involves assessments of both plasma cell-surface antigens and immunoglobulin light-chain expression.
Some Targeted Therapies May Miss the Mark
Ten different drugs continued to kill cancer cells even when their target proteins were removed.
Frailty Score May Predict Outcomes in Multiple Myeloma
Frailty score based on age, Charlson Comorbidity Index, ECOS PS predicts outcomes in FIRST trial.
Circulating Tumor Plasma Cells Predict Progression in Myeloma
The presence of circulating tumor plasma cells by next-generation flow independently predicted disease progression after treatment in patients with multiple myeloma.
Isatuximab Plus Pomalidomide and Dexamethasone May Improve Survival in Relapsed/ Refractory Multiple Myeloma
Patients who received isatuximab experienced a median progression-free survival of 11.5 months compared with 6.5 months in patients who did not receive isatuximab.
Long-Term Follow-Up of BCMA-Directed CAR-T in R/R MM: CRs Appear Durable in LEGEND-2
Long-term follow-up from the clinical trial investigating LCAR-B38M, a BCMA-targeting CAR-T, revealed that approximately three-quarters of patients achieved a complete response.
Evidence of Clinical Benefit for Bispecific Antibody in Patients With Refractory Multiple Myeloma
This dose-finding study examined a bispecific antibody targeting BCMA and CD3 in patients with R/R multiple myeloma.
Next post in ASH 2019
